摘要 |
Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R<SUP>1 </SUP>represents a group selected from H, CF<SUB>3</SUB>, and C<SUB>1-6 </SUB>alkyl (optionally substituted by C<SUB>1-6 </SUB>alkyloxy or triazolyl); R<SUP>2 </SUP>represents halo; Ring A represents a 5- or 6-membered heterocyclic ring containing at least one N atom (the ring being optionally bridged with two or more carbon atoms); R<SUP>3 </SUP>represents a 5- or 6-membered heterocyclic ring containing at least one atom selected from N, O or S, the heterocyclic ring being optionally substituted by one or more groups selected from C<SUB>1-6 </SUB>alkyl oxo or NH<SUB>2</SUB>, the heterocyclic ring being further optionally fused to a 5- or 6-membered aryl or heterocyclic ring containing at least one atom selected from N, O or S, the fused aryl or heterocyclic ring being substituted by one or more halo atoms; are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhea.
|